StreetInsider.com News Articles

Sibylla Biotech names new CEO and CFO to advance oncology pipeline

Tue, 13 Oct 2026 05:00:17 -0400

Sibylla Biotech, a Milan-based oncology biotechnology company, announced the appointment of Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta as Chief Financial Officer, according to a company statement dated October 13, 2026.

Co-founder and former CEO Lidia Pieri will transition to Chief Operating Officer, while Elena Ardini has been promoted from Vice President of Research and Development to Chief Scientific Officer.

Dr. Azam brings more than 25 years of biopharmaceutical experience. He most recently served as CEO of CUE Biopharma, and previously held CEO roles at Inspirna, Inc. and Empyrean Neuroscience. He also served as President and CEO of Tmunity

Sibylla Biotech names new CEO and CFO to advance oncology pipeline

Tue, 13 Oct 2026 05:00:17 -0400

Co-founder and former CEO Lidia Pieri will transition to Chief Operating Officer, while Elena Ardini has been promoted from Vice President of Research and Development to Chief Scientific Officer.

Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic

Tue, 13 Oct 2026 05:00:00 -0400

Lidia Pieri to serve as Chief Operating Officer and Elena Ardini promoted to Chief Scientific Officer
Cyclin D1-targeting folding-interfering degrader advances as Sibylla’s lead program

Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership. Co-founder and previous CEO Lidia Pieri, PhD, MBA, will remain

Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic

Tue, 13 Oct 2026 05:00:00 -0400

Lidia Pieri to serve as Chief Operating Officer and Elena Ardini promoted to Chief Scientific Officer
Cyclin D1-targeting folding-interfering degrader advances as Sibylla’s lead program

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

Thu, 08 Oct 2026 07:00:00 -0400

BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12^th to 14^th at The Hard Rock Hotel New York, in New York City.

Gain Therapeutics will be meeting with institutional investors in one-on-one meeting sessions and engaging with senior Maxim research analysts throughout the event.

If you are interested in meeting with Gain management, please

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

Thu, 08 Oct 2026 07:00:00 -0400

Gain Therapeutics will be meeting with institutional investors in one-on-one meeting sessions and engaging with senior Maxim research analysts throughout the event.

If you are interested in meeting with Gain management, please

BTIG Reiterates Buy Rating on Gain Therapeutics (GANX)

Mon, 05 Oct 2026 08:46:20 -0400

BTIG analyst Thomas Shrader reiterated a Buy rating and $5.00 price target on Gain Therapeutics (NASDAQ: GANX).

The analyst comments "The P1b trial at 1 year reinforces what the earlier readouts have suggested - GT-02287 shows a pronounced ability to freeze the progression of clinically accepted symptoms in relatively advanced PD patients (Exhibit 1 shows stabilization). These results, like any small data set, need to be repeated, but the 1- year data should raise confidence in the next trial based on the historical expectation that this group of patients is expected to decline by about 6 points per year based on

Gain Therapeutics reports rexaceract motor score stability at 12 months

Thu, 01 Oct 2026 09:29:07 -0400

Gain Therapeutics, Inc. (Nasdaq: GANX) presented open-label extension data from its Phase 1b clinical study of rexaceract, a drug candidate for Parkinson's disease, showing stabilization of motor symptom scores over 12 months of daily oral dosing, according to a press release from the company.

The data were presented as a poster at the International Congress of Parkinson's Disease and Movement Disorders, held October 4-8, 2026, in Seoul, Korea.

As of August 31, 2026, 12 of 13 evaluable participants had completed the full 12-month administration of rexaceract. MDS-UPDRS Parts II and III motor scores remained stable from baseline through the study period, with

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

Thu, 01 Oct 2026 09:28:00 -0400

MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026

Participants with both high and low baseline levels of GluSph experienced stabilization of MDS-UPDRS motor scores by 12 months

Results support disease-modifying potential of rexaceract along with a favorable tolerability profile; no significant safety signals observed in the Phase 1b

BETHESDA, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

Thu, 01 Oct 2026 09:28:00 -0400

Participants with both high and low baseline levels of GluSph experienced stabilization of MDS-UPDRS motor scores by 12 months

Results support disease-modifying potential of rexaceract along with a favorable tolerability profile; no significant safety signals observed in the Phase 1b

BETHESDA, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a

Form 8-K Gain Therapeutics, Inc. For: Oct 01

Thu, 01 Oct 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20261001/27132863.html

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

Tue, 29 Sep 2026 17:50:00 -0400

BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea.

Details of the poster and presentation are as follows:

Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 (Rexaceract) in People with Parkinson’s Disease

E-Poster Number: 753

Presentation Date: October 7, 2026

Presentation Time: 12:00-12:10pm

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

Tue, 29 Sep 2026 17:50:00 -0400

Details of the poster and presentation are as follows:

Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 (Rexaceract) in People with Parkinson’s Disease

E-Poster Number: 753

Presentation Date: October 7, 2026

Presentation Time: 12:00-12:10pm

Form 8-K Gain Therapeutics, Inc. For: Sep 22

Mon, 28 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260928/27114975.html

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

Thu, 17 Sep 2026 07:00:00 -0400

BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in an industry panel and one-on-one meetings at the ROTH Fifth Annual Healthcare Opportunities Conference, held September 29^th at the Metropolitan Club in New York, NY.

Presentation Information

Presentation Title: Frontiers in Neuroscience

Date: Tuesday, September 29, 2026

Time: 11:00 a.m. ET

Registered attendees can request one-on-one meetings

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

Thu, 17 Sep 2026 07:00:00 -0400

Presentation Information

Presentation Title: Frontiers in Neuroscience

Date: Tuesday, September 29, 2026

Time: 11:00 a.m. ET

Registered attendees can request one-on-one meetings

H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Mon, 31 Aug 2026 06:54:10 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $8.00 price target on Gain Therapeutics (NASDAQ: GANX).

The analyst commented: "We remind investors that Gain Therapeutics has received FDA authorization for the company’s Investigational New Drug (IND) application for its lead candidate GT-02287 (International Non-proprietary Name rexaceract). The FDA’s decision will allow the start of Gain’s Phase 2 clinical assessment of GT-02287 in Parkinson’s disease (PD) with or without a GBA1 mutation in the U.S. Both the Phase 1a and Phase 1b studies of GT-02287 were conducted in Australia. The sites in Australia are expected to also participate in the

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Tue, 25 Aug 2026 07:00:00 -0400

BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in one-on-one meetings at the H.C. Wainwright 28^th Annual Global Investment Conference, held September 14-16 in New York City, NY.

On-demand Company Presentation

Date and Time: Friday, September 11, 2026; replay available beginning 7:00 a.m. ET

Access a replay here or visit the “Investors & Media/News & Events”

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

Tue, 25 Aug 2026 07:00:00 -0400

On-demand Company Presentation

Date and Time: Friday, September 11, 2026; replay available beginning 7:00 a.m. ET

Access a replay here or visit the “Investors & Media/News & Events”

Form 10-Q Gain Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905713.html

Form 10-Q Gain Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905713.html

Form 8-K Gain Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905609.html

Form 8-K Gain Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26905609.html

Gain Therapeutics, Inc. (GANX) Tops Q2 EPS by 3c

Tue, 11 Aug 2026 07:20:31 -0400

Gain Therapeutics, Inc. (NASDAQ: GANX) reported Q2 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Gain Therapeutics, Inc. (GANX) click here.

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.

“The second quarter marked an important period of execution for Gain, highlighted by FDA authorization of our IND for rexaceract, which positions us to advance into Phase 2 clinical development,” said Gene Mack, President and CEO of Gain Therapeutics. “The encouraging biomarker and clinical